Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
7 hedge funds and large institutions have $747K invested in Aridis Pharmaceuticals Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
57% more capital invested
Capital invested by funds: $477K → $747K (+$270K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$354K |
| 2 |
Millennium Management
New York
|
+$234K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$8.55K |
| 4 |
Morgan Stanley
New York
|
+$2.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $551K | +$354K | +38,685 | +89% |
|
|
2
Millennium Management
New York
| $171K | +$234K | +25,569 | New |
|
3
BlackRock
New York
| $8K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $7K | -$9.5K | -1,038 | -50% |
|
|
5
Victory Capital Management
San Antonio,
Texas
| $6K | +$8.55K | +934 | New |
|
6
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
7
Morgan Stanley
New York
| $2K | +$2.1K | +229 | New |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$1K | -114 | Closed |
|
ARDS Hedge Fund Activity: Q3 2019 in Review
7 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q3 2019, worth a combined $747K — up 57% from $477K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ARDS positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $354K. The largest seller was UBS Group, cutting an estimated $9.5K.
- 7 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q3 2019, up from 6 in Q2 2019.
- Funds reported $747K of Aridis Pharmaceuticals Inc. Common Stock stock for Q3 2019, up 57% quarter-over-quarter.
- 3 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q3 2019 and 2 closed out, a net change of +1 holder.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $354K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q3 2019 was UBS Group, an estimated $9.5K sold.
Based on aggregated 13F filings for Q3 2019.